New Paradigms in Heart Failure: RAAS Inhibition and the Management of Hyperkalaemia

This symposium took place on 29th August 2015 as a part of the European Society of Cardiology Congress in London, UK

Chair: John McMurray1
Speakers: Faiez Zannad,2 Ileana L. Piña,3 John McMurray1

1. University of Glasgow, Glasgow, UK
2. Henri Poincaré University of Nancy, Nancy, France
3. Montefiore-Einstein Medical Centre, Bronx, New York, USA

Disclosure: John McMurray has no relevant disclosures to declare. Faiez Zannad has acted on steering committees for Bayer, Boston Scientific, Novartis, Pfizer, ResMed, and Takeda; acted as a consultant and advisory board member for Air Liquide, Amgen, CVRx, Relypsa, Servier, St Jude, Stealth Peptide, ZS Pharma, and Quantum Genomics; and received a research grant from Roche Diagnostics. Ileana Piña has acted as a consultant and advisory board member for ZS Pharma.
Acknowledgements: Writing assistance was provided by Dr Lucy Smithers of ApotheCom and funded by ZS Pharma Inc.
Support: The symposium was organised by Medavera, Inc. and supported by an educational grant from ZS Pharma Inc. Authors received honoraria for preparation and delivery of their presentations. The paper is an interpretation of the views of the speakers, but is not written by them. The views and opinions expressed are those of the authors and not necessarily of Medavera, Inc. or ZS Pharma Inc.
Citation: EMJ Cardiol. 2015;3[2]:53-61.

Meeting Summary

This educational symposium discussed advances in blocking the renin–angiotensin–aldosterone system (RAAS) for patients with chronic systolic heart failure (HF), and the issues of managing hyperkalaemia in these patients.

Prof John McMurray introduced the session, outlining the current treatment paradigm and the challenges presented by the associated risks of hyperkalaemia. Prof Faiez Zannad discussed the under-utilisation of life-saving RAAS inhibitor (RAASi) drugs in clinical practice and the benefits to be gained for patients by optimising their use. Prof Ileana Piña reviewed current advances in pharmacological treatments for chronic HF that aim to reduce the risks of renal dysfunction and hyperkalaemia. Finally, Prof John McMurray discussed the potential of new treatment paradigms for improved outcomes in patients with chronic HF.

Download (PDF, 132KB)

Comments are closed.